ConnectM Receives $1.60 Per Share Buyout Offer from its 3 Largest Institutional Investors

 ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) ("ConnectM" or the "Company"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.

The offer, submitted on March 31, 2025, implies a total equity valuation of approximately $46.5 million for ConnectM.

SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd. have been long-term investors in ConnectM, having initially invested in the Company in 2020. In recent months, the investor group has significantly increased their ownership positions, reflecting a deepened commitment to the Company's strategic vision and long-term potential.

The proposed transaction, if accepted, would result in the privatization of ConnectM and is subject to the completion of customary due diligence, definitive agreements, and regulatory approvals.

https://www.prnewswire.com/news-releases/connectm-receives-1-60-per-share-buyout-offer-from-its-three-largest-institutional-investors-302418327.html

Greenwich LifeSciences Positive Immune Response Data from Phase III Breast Cancer Trial

 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data.

The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over time as the frequency of patients exhibiting an injection site reaction or GP2 Delayed-Type Hypersensitivity (DTH) skin test reaction as measured by induration or erythema is increasing with increased vaccinations.

• The number of patients experiencing an immune response increased over time from baseline through the 4th to 6th month vaccinations in both HLA-A*02 and non-HLA-A*02 arms.
• In addition, a baseline immune response to GP2 is being observed before any treatment with GP2 in both HLA-A*02 and non-HLA-A*02 arms. This result suggests that GP2 is a natural antigen, that may have been part of an immune response in the patient during prior trastuzumab or other treatments.
• These two general immune response findings, immune response at baseline and increasing immune response over time, were also observed in the Phase IIb clinical trial for HLA-A*02 only patients. These results confirm that the HLA prevalence, safety, and immune response in FLAMINGO-01 patients is trending as expected in both HLA arms.
• The Company recently filed patent claims for non-HLA-A*02 patients which may be solely owned by the Company separate from any prior license. These claims are also supported by binding prediction algorithms and in vitro binding experiments conducted by the Company. This represents an invention that was originated by the Company which could double the number of patients eligible for GP2 treatment to approximately 88,000 new patients per year in the US and Europe. The market potential using the drug prices per year of Kadcyla or Enhertu could be in the range of $8-10 billion per year.
• As mentioned in a prior press release, the non-HLA-A02 types that are most commonly being enrolled in FLAMINGO-01 include HLA-A*03, HLA-A*24, HLA-A*01, HLA-A*11, HLA-A*68, HLA-A*29, HLA-A*30, HLA-A*23, and HLA-A*33.
  

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label immune response data is based on the patients enrolled to date in FLAMINGO-01 and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results and the results at the end of the study may differ.

https://www.globenewswire.com/news-release/2025/04/02/3054058/0/en/Greenwich-LifeSciences-Announces-Positive-Immune-Response-Data-from-FLAMINGO-01-Phase-III-Clinical-Trial.html

Sunshine Biopharma Positive Results of mRNA Therapy for Cancer

 Sunshine Biopharma Inc. (NASDAQ:SBFM) ("We", "Our", the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma.

Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several treatment options were made available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.

We have optimized the expression level of our full-length mRNA (K1.1c) as well as a smaller, truncated version (K1.1d) in HCC tumors in mice. Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a dose-dependent manner by systemic administration. Under repeated dosing, the full-length K1.1c was found to reduce growth of three different types of human HCC tumors in mice with good tolerability. Proof-of-concept study of the truncated version K1.1d was conducted to assess its anti-tumor activity in HCC models in mice. A preliminary study suggested the truncated form of K1.1c could be highly expressed in engrafted tumors and had significant anti-tumor activity in mouse HCC models in a dose-dependent manner.

We are currently conducting additional animal studies to delineate optimum dosing of our truncated version (K1.1d) in different HCC model in mice to compare its dose-response and therapeutic window with those of the full-length (K1.1c). The smaller-sized mRNA of the truncated version offers the advantage of better efficacy at lower doses.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/sunshine-biopharma-announces-positive-results-of-mrna-therapy-for-can-1009138

ReShape Lifesciences shareholders approve key proposals

 ReShape Lifesciences Inc. (NASDAQ:RSLS), a pharmaceutical company, announced the outcomes of several critical votes taken at its special meeting on April 1, 2025. The voting results, disclosed in an SEC filing on April 2, 2025, indicate shareholder approval on all proposed items, including a reverse stock split, warrant exercisability, and an Equity Line of Credit (ELOC) agreement. According to InvestingPro data, the company’s stock has shown remarkable volatility, with a 236% return over the past week, though it remains 71% lower over the past six months.

The first proposal, which passed with 2,267,177 votes in favor, grants the company’s Board of Directors the authority to implement a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-250 within one year from the meeting date. The exact ratio and timing will be determined by the Board and subsequently announced to the public. InvestingPro analysis reveals the company maintains a positive cash position relative to debt, though it’s currently experiencing rapid cash burn - just two of the 14+ insights available to subscribers.

The second proposal, receiving 106,509 affirmative votes, pertains to the exercisability of 2,703,862 common stock purchase warrants. These warrants were issued in association with a securities offering on February 18, 2025, to certain institutional investors and the company’s placement agent. The approval aligns with Nasdaq Listing Rule 5635(d) and permits the issuance of up to 15,132,975 shares of common stock underlying the warrants, which may be exercised without an exercise price.

Additionally, the third proposal, which garnered 1,444,858 votes for approval, allows for the issuance of common stock under the ELOC Purchase Agreement dated December 19, 2024. The agreement with an institutional investor permits ReShape Lifesciences to sell up to $5 million in shares over a 36-month term, subject to the terms and conditions outlined in the agreement.

These approvals by the company’s stockholders are expected to provide ReShape Lifesciences with the flexibility to manage its capital structure and funding strategy effectively. With a current market capitalization of $5.26 million and a gross profit margin of 68.19%, the company faces significant challenges, as indicated by its negative EBITDA of -$7.9 million in the last twelve months. The company, formerly known as Obalon Therapeutics (NASDAQ:OBLN_old) Inc., specializes in pharmaceutical preparations and operates under the organization name 03 Life Sciences, based in Irvine, California. For detailed analysis and comprehensive insights, investors can access the full Pro Research Report available on InvestingPro.

This news article is based on a press release statement and should be considered as information obtained from the company’s SEC filing.

In other recent news, ReShape Lifesciences has been granted an international patent by the State of Israel Patent Office for its Diabetes Neuromodulation technology, which is designed to improve glycemic control for Type 2 diabetes patients. This patent extends protection until December 2039 and is part of ReShape’s extensive intellectual property portfolio, which includes 62 issued or pending patents. Additionally, ReShape Lifesciences has amended the terms of its senior secured convertible note with Ascent Partners Fund LLC, extending the note’s maturity and adjusting prepayment conditions. This amendment is strategically aligned with ReShape’s anticipated merger with Vyome Therapeutics, Inc., providing financial flexibility ahead of the merger.

The merger between ReShape Lifesciences and Vyome Therapeutics is progressing as planned in an all-stock transaction, with ReShape set to become Vyome Holdings, Inc. and expected to trade on Nasdaq under the ticker "HIND." As part of this strategic move, ReShape has also entered into an asset purchase agreement with Biorad Medisys, which will acquire the Lap-Band, Obalon Gastric Balloon, and Diabetes Bloc-Stim Neuromodulation systems. The merger will result in a new management structure led by Vyome’s executive officers and aims to leverage U.S.-India synergies to develop therapies for chronic immune-inflammatory conditions. Paul F. Hickey, President and CEO of ReShape, has expressed confidence in the merger’s potential to create significant shareholder value.

https://www.investing.com/news/sec-filings/reshape-lifesciences-shareholders-approve-key-proposals-93CH-3962532

Unearthed FBI Chat Logs Reveal 'Gag Order' On Biden Laptop Exposé

 by Luis Cornelio via Headline USA,

Internal FBI chat logs revealed that the bureau imposed a “gag order” on agents regarding the New York Post bombshell story on the Hunter Biden laptop. Along with showing Hunter’s depravity, the laptop revealed Joe Biden’s involvement in his son’s foreign business dealings. 

The chat logs, published Tuesday by the House Judiciary Committee on X, show that the gag order extended to an FBI analyst who attempted to alert social media companies that the laptop was authentic—before these companies moved to censor the story’s spread. 

On Oct. 14, 2020, the New York Post released its first story on the laptop’s content. That same day, FBI officials instructed agents, “please do not discuss Biden matter.” 

Earlier chats show a group of agents—including Laura Dehmlow, Bradley Benavides and James Dennehy—debating the Post’s story.

“You guys are tracking the coverage of the laptop right?” Dehmlow wrote. Both Benavides and Dennehy replied affirmatively. 

Later, agents whose names remain sealed sent messages stating, “right answer – nobody on call is is [sic] authorized to comment upon NY Post story” and “nobody [is] authorized to comment.” 

One agent asked if another had “admonished” the colleague who nearly revealed the laptop’s authenticity to Big Tech companies. “yes but he wont [sic] shut up,” one response read. 

Hours later, agents reiterated that they were forbidden from commenting on the laptop story, with messages like “official response no commen [sic] and “we cannot comment.” 

A previous transcribed interview with Dehmlow revealed that during a Zoom meeting with Big Tech, an FBI agent was interrupted before he could confirm the laptop was real and already in the bureau’s possession. 

The FBI had verified the laptop in 2019 by cross-referencing its serial number with Hunter’s iCloud storage, FBI special agent Erika Jensen stated during Hunter’s criminal trial in 2024. 

Despite this verification, the bureau remained silent while social media companies debated whether the Post’s story was tied to a Russian disinformation campaign.

Notably, the FBI had warned them weeks earlier of an imminent “hack-and-leak” story about the 2020 election, leading many to mistakenly equate that warning with the laptop exposé. 

The laptop revealed that while Hunter failed to pay millions in taxes, he also consumed drugs, paid for prostitutes and launched what Republicans call an “influence-peddling scheme” aimed at selling access—or at least the appearance of access—to Joe Biden in exchange for payments. 

According to the laptop, 10% of these payments were earmarked for the “Big Guy,” a term confirmed by former Biden ally Devon Archer to refer to Joe Biden. 

Biden went on to win the 2020 election, and before leaving office in 2025, he issued sweeping pardons to his siblings and Hunter, covering offenses committed between 2014 and 2025.

Read the full House Judiciary Committee’s X thread on the chatlogs:

https://www.zerohedge.com/political/unearthed-fbi-chat-logs-reveal-gag-order-biden-laptop-expose

Bipartisan Senators Prepare 500% Uranium, Oil Tariffs If Russia Doesn't Negotiate

 A bipartisan group of US senators have prepared an anti-Russia sanctions nuclear option in the case that Moscow refuses to sign on to Trump efforts to negotiate an end to the Ukraine war.

The 50 Republicans and Democrats which introduced the sanctions package Tuesday are led by Senators Lindsey Graham and Richard Blumenthal, and their bill would impose a 500% tariff on imported goods from countries that buy Russian oil, gas, uranium and several other products. American citizens would also be prohibited from buying Russian sovereign debt.

"The sanctions against Russia require tariffs on countries who purchase Russian oil, gas, uranium and other products. They are hard hitting for a reason," the Senators wrote in a Tuesday statement.

Getty Images

"These sanctions against Russia are at the ready and will receive overwhelming bipartisan, bicameral support if presented to the Senate and House for a vote," they added.

"The dominating view in the United States Senate is that Russia is the aggressor, and that this horrific war and Putin’s aggression must end now and be deterred in the future."

This in part springs from growing concern that despite President Trump's good-faith efforts, even dangling the possibility of dropping sanctions to get the Kremlin quickly to the negotiating table, Moscow is intentionally stalling while it presses the war forward.

President Trump told reporters over the weekend aboard Air Force one of Putin and his officials, "If I think they’re tapping us along, I will not be happy about it."

China and India would come under the immediate crosshairs, as they've remained top importers of Russian oil since the start of the Ukraine war.

However, the bill leaves open the option of granting presidential waivers on national security grounds, with Bloomberg pointing to the likely chance of a "confrontation" with India and China over the secondary sanctions and the "difficult position" the EU has found itself in.

In Europe, the lure of a return to cheap Russian energy is ever-present, and as we noted, senior German politicians are already calling for a resumption of ties with Russia. For example Michael Kretschmer, a senior member of Friedrich Merz’s centre-right Christian Democrats, is now arguing that EU sanctions on Russia are "completely out of date" as they increasingly openly contradict "what the Americans are doing."

Financial Times in a report quoted Kretschmer's words to the German press agency DPA as follows: "When you realize that you’re weakening yourself more than your opponent, then you have to think about whether all of this is right."

50 US Senators have introduced a bill that includes the most intense Russia sanctions to date including a 500% (!) additional tariff on any countries buying Russian hydrocarbons & uranium, putting SWIFT into law, and perma-freezing Russian sovereign debt & securities. Wow. pic.twitter.com/Mg8hJIN1oY

— Maximilian Hess (@zakavkaza) April 2, 2025

At the same time, Hungary and Slovakia not only continue bypassing Ukraine for imports of Russian gas - after Ukraine broke from the transit of Russian gas on January 1st - but are actually boosting these supplies.

Hungarian Foreign Minister Peter Szijjarto announced on Tuesday that the Veľké Zlievce/Balassagyarmat interconnection point from Hungary to Slovakia has been brought to full capacity this week due to the stoppage through Ukraine.

https://www.zerohedge.com/geopolitical/bipartisan-group-senators-prepare-500-uranium-oil-tariffs-if-russia-doesnt-negotiate

Walmart continues to push Chinese suppliers to cut prices, Bloomberg says

 U.S. retailing giant Walmart (WMT) is continuing to push Chinese suppliers to cut prices to offset President Donald Trump's tariffs, Bloomberg News reported on Tuesday, citing people familiar with the matter.

Some Chinese manufacturers are finding it difficult to meet Walmart's demands to cut prices by as much as 10% for each round of Trump's tariffs, the report said.

Walmart did not immediately respond to Reuters' request for comment outside business hours.

Beijing officials met with Walmart last month to discuss media reports that the U.S. retailer has asked Chinese suppliers to slash prices on their goods to offset the impact of the Trump administration's tariffs.

Walmart has been working to mitigate the impact of tariffs since U.S. President Donald Trump's first term by diversifying its supply chain and reducing its reliance on China.

However, China remains a significant source for Walmart's discretionary merchandise, such as clothing, electronics, and toys. A substantial portion of these imports, including items like Reebok shoes, Mattel toys, Onn TVs, t-shirts, belts, shoes, and appliances, still come from China.

https://finance.yahoo.com/news/walmart-continues-push-chinese-suppliers-030409342.html